Feedstock-efficient conversion through hydrogen and formate-driven metabolism in Escherichia coli
- PMID: 41106462
- DOI: 10.1016/j.ymben.2025.10.003
Feedstock-efficient conversion through hydrogen and formate-driven metabolism in Escherichia coli
Abstract
Product yields for biomanufacturing processes are often constrained by the tight coupling of cellular energy generation and carbon metabolism in sugar-based fermentation systems. To overcome this limitation, we engineered Escherichia coli to utilize hydrogen gas (H2) and formate (HCOO-) as alternative sources of energy and reducing equivalents, thereby decoupling energy generation from carbon metabolism. This approach enabled precise suppression of decarboxylative oxidation during acetate growth, with 86.6 ± 1.6 % of electrons from hydrogen gas (via soluble hydrogenase from Cupriavidus necator H16) and 98.4 ± 3.6 % of electrons from formate (via formate dehydrogenase from Pseudomonas sp. 101) offsetting acetate oxidation. Hydrogen gas supplementation led to a titratable and stoichiometric reduction in CO2 evolution in acetate-fed cultures. Metabolomic analysis suggests that this metabolic decoupling redirects carbon flux through the glyoxylate shunt, partially bypassing two decarboxylative steps in the TCA cycle. We demonstrated the utility of this strategy by applying it to mevalonate biosynthesis, where formate supplementation during glucose fermentation increased titers by 57.6 % in our best-performing strain. Flux balance analysis further estimated that 99.0 ± 2.8 % of electrons from formate were used to enhance mevalonate production. These findings highlight a broadly applicable strategy for enhancing biomanufacturing efficiency by leveraging external reducing power to optimize feedstock and energy use.
Keywords: Biomanufacturing; Energy innovation; Formic acid; Gas fermentation; Hydrogen; Industrial microbiology; Metabolic flux analysis; NADH.
Copyright © 2025 International Metabolic Engineering Society. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest statement RLB declares a financial interest in Redoxify. JBR declares a financial interest in AlkaLi Labs. JDK declares a financial interest in Ansa Biotechnologies, Apertor Pharma, Berkeley Yeast, BioMia, Cyklos Materials, Demetrix, Lygos, Napigen, ResVita Bio, and Zero Acre Farms. Given his role as co-Editor in Chief of Metabolic Engineering, JDK had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to another journal editor. RLB, JP, SWS, and JDK declare a financial interest in U.S. Provisional Patent and Patent Cooperation Treaty application, entitled “A host cell with increased cellular reducing power from a heterologous hydrogenase” (No. WO2024197170A3). All other authors declare no competing interests.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
